Tomato Zonate Spot Virus Detection Reagent

Abstract

This invention provides a tomato zonate spot virus detection reagent. Optimized gene encoding N protein of TZSV is expressed and purified to obtain N protein of TZSV, and two specific hybridoma cell lines are obtained, from which specific anti-TZSV monoclonal antibody could be obtained, respectively. Test strip for detecting tomato zonate spot virus is prepared with the monoclonal antibody. It is proven by experiments that the test strip of this invention is specific for TZSV, and can realize rapid detection of TZSV in leaves and other samples, with high sensitivity and convenient operation.

Claims

1. Hybridoma cell lines whose depository numbers are CCTCC No. C202160 and CCTCC No. C202196.

2. Use of the hybridoma cell lines of claim 1 in preparing anti-tomato zonate spot virus monoclonal antibody.

3. Anti-tomato zonate spot virus monoclonal antibody generated by hybridoma cell lines whose depository numbers are CCTCC No. C202160 and CCTCC No. C202196.

4. Use of the monoclonal antibody of claim 3 in preparing tomato zonate spot virus detection reagent.

5. Gene with nucleic acid sequence as shown in SEQ ID NO:2.

6. Use of the gene of claim 5 in preparing anti-tomato zonate spot virus monoclonal antibody.

7. A reagent for detecting tomato zonate spot virus, characterized in that, comprising monoclonal antibody generated by the hybridoma cell lines of claim 1.

8. The reagent for detecting tomato zonate spot virus of claim 7 , is a test strip consisting of a sample pad, a gold labeled pad, a nitrocellulose membrane, an absorbent pad and a backplane; the sample pad, gold labeled pad, nitrocellulose membrane and absorbent pad are successively superimposed and pasted on the backplane, and each part is superimposed between each other by 2-3 mm; the gold labeled pad was coated with colloidal gold labeled anti-tomato zonate spot virus monoclonal antibody; nitrocellulose membrane is provided with a test line and a quality control line, the test line is coated with anti-tomato zonate spot virus monoclonal antibody, the quality control line is coated with anti-mouse IgG secondary antibody.

9. The reagent for detecting tomato zonate spot virus of claim 7, wherein the sample pad is glass cellulose membrane.

10. The reagent for detecting tomato zonate spot virus of claim 7, wherein concentration of colloidal gold labeled anti-tomato zonate spot virus monoclonal antibody coated on the gold labeled pad is 0.3-0.5 mg/ml.

11. The reagent for detecting tomato zonate spot virus of claim 7, wherein concentration of anti-tomato zonate spot virus monoclonal antibody coated by the test line is 0.5-1.5 mg/ml.

12. The reagents for detecting tomato zonate spot virus of claim 7, wherein the backplane is a PVC plate.

Description

DESCRIPTION OF DRAWINGS

[0030] FIG. 1 is structure diagram of the TZSV handheld colloidal gold rapid test strip of the present invention; wherein, 1 is the result observation area, 2 is the marking area, 3 is the quality control area (C), 4 is the test area (T), 5 is the sample adding area.

[0031] FIG. 2 shows specific detection of the TZSV test strip of the present invention. From left to right, leaf samples positive for tobacco viruses TMV, PVY, TSWV, ChiVMV and TZSV determined by RT-PCR are shown.

[0032] FIG. 3 shows electrophoretic diagram of PET28A-TZSV-N protein purification in example 6 of the present invention.

[0033] FIG. 4 shows the 9# monoclonal antibody standard curve of example 6 of the present invention.

[0034] FIG. 5 shows sensitivity test result of TZSV test strip in example 6 of the present invention.

[0035] FIG. 6 shows specific detection result of the TZSV test strip of example 6 of the present invention.

EMBODIMENTS

[0036] The following examples are used to illustrate the invention without limiting scope of the invention. Unless otherwise specified, technical means used in the examples are conventional means well known to a person skilled in the art, and the raw materials used are commercially available goods.

Example 1. Expression and Purification of TZSV Protein

Test Expression of Protein

[0037] 1. Sequence synthesis: According to protein sequence, optimized sequence was synthesized and cloned into vector pET30a, and the sequence was synthesized by Sangon Bioengineering (Shanghai) Co., LTD. Amino acid sequence of tomato zonate spot virus protein was shown as SEQ ID NO: 1. Nucleic acid sequence of the optimized tomato zonate spot virus gene is shown as SEQ ID NO:2.

[0038] 2. Strain activation: PET30a-TZSV plasmid was transformed into BL21 (DE3) and coated on LB solid medium (Kanamycin concentration of 50 .Math.g/mL). Next day, monoclonal colonies were selected and added into 5 mL LB liquid medium (Kanamycin concentration 50 .Math.g/mL) and cultured at 37° C. for 12 h-14 h. Original sequence of protein was SEQ ID NO: 1.

[0039] 3. Small test expression: next day, strains were added into 5 mL LB liquid medium at 1:50 (Kanamycin concentration of 50 .Math.g/mL) and cultured at 37° C. until OD=0.4-0.6. After centrifugation, 1 mL of bacterial solution was absorbed and centrifuged for using as control before induction. 4 mL of bacterial solution was added with 0.8 mM IPTG, induced and expressed at 25° C. for 6 h, after that, the bacterial solution was centrifuged at 8000 RPM and 4° C. for 1 min and collected.

[0040] 4. Identification of protein expression form: above expressed bacteria were added to 1 mL crushing solution for ultrasonic lysis. Lysis conditions: temperature ice bath, power 40%, ultrasonic 2 s, 2 s interval, time 30 min. Supernatant and precipitate were collected after centrifugation at 12000 rpm and 4° C. for 1 min. Result of SDS-PAGE showed that target protein was mainly expressed in soluble form.

Mass Expression and Purification of Protein

[0041] 1. Strain activation: pET30a-TZSV colonies were selected from solid plates and added into 5 mL LB liquid medium (Kanamycin concentration 50 .Math.g/mL), and incubated at 37° C. for 12 h-14 h.

[0042] 2. Small test expression: next day, strains were added into 800 mL LB liquid medium at 1:50 (Kanamycin concentration of 50 .Math.g/mL), cultured at 37° C. to OD=0.4-0.6, and IPTG was added at 0.8 mM. After induction and expression at 25° C. for 6 h, bacteria was centrifuged at 8000 RPM and 4° C. for 15 min and collected.

[0043] 3. Strain lysis: 100 mL crushing solution was added for ultrasonic lysis. Lysis conditions: temperature ice bath, power 60%, ultrasonic 2 s, interval 2 s, time 15 min. Supernatant and precipitate were collected after centrifugation at 12000 RPM and 4° C. for 15 min.

[0044] 4. Purification of supernatant: The collected supernatant was purified by high affinity Ni resin, and the flowing through fluid and eluent were collected. Results of SDS-PAGE showed that 50 mM imidazole elution had best purity of protein. The imidazole was removed by dialysis with 50 mM imidazole eluent, and effect of dialysis was detected by SDS-PAGE, and results showed that purity and concentration of protein after dialysis were feasible. After detection, finally, purity of target protein was more than 90%, concentration was 2 mg/mL, and protein amount was 10 mg.

Results

[0045] Expression conditions of pet30a-tzsv protein were as follows: IPTG concentration was 0.8 mM, induction temperature is 25° C., induction time is 6 h. Protein was mainly expressed in supernatant, which was purified by Ni column and dialyzed to remove imidazole, and in final, TZSV N protein was obtained with concentration of 2 mg/mL, purity more than 90%, protein of 10 mg.

Example 2. Antibody Preparation

Preparation of Monoclonal Antibody

[0046] 1. Immunogen preparation: The expressed and purified protein was mixed and emulsified with equal volume of Freund’s adjuvant to form a water-in-oil state for immunizing mice.

[0047] 2. Immunization strategy: 4 Balb/c mice were immunized with protein for 3 times subcutaneously, with an interval of 4 weeks, and finally titer was detected by indirect ELISA. [0048] The steps of indirect ELISA method are as follows: [0049] 1) The purified protein was diluted with 0.1 mol/L carbonate buffer, pH=9.6 to 1 .Math.g/ml, then added to 96-well microplate, 100 .Math.l in each well, and reacted at 37° C. for 3 h or placed at 4° C. overnight. [0050] 2) Liquid in the plate well was shaken off, and 250 .Math.l washing buffer was added to stand for 30 s, then liquid in the plate was shaken off. Such operation was repeated for 3 times. [0051] 3) test samples were added with 100 .Math.l to each well, and positive control (positive mouse serum obtained in step (2)), negative control (mouse serum before immunization) and blank control (without mouse serum) were added simultaneously for reacting at 37° C. for 45 min. [0052] 4) Repeat step 2); [0053] 5) HRP labeled sheep anti-mouse enzyme-conjugated secondary antibody was added with 100 .Math.l per well, and react at 37° C. for 45 min. [0054] 6) Repeat step 2); [0055] 7) chromogenic agent was added with 100 .Math.l to each well, and react at room temperature for 15 min in the dark. [0056] 8) stop solution was added with 100 .Math.l in each well, and OD value was read at wavelength 450 using a microplate reader. Antiserum titer is shown in Table 1:

TABLE-US-00001 Animal number 100 1K 3K 9K 27K 81K 243K Negative control Titer Immunization schedule M210045 3.9064 3.7261 3.7004 3.6867 3.0881 2.472 1.7417 0.1373 > 1:243000 secondary immunization M210046 3.3312 3.1428 3.0632 2.3105 1.5738 0.8598 0.4183 0.1461 > 1:243000 secondary immunization M210047 3.1319 2.5112 1.6485 0.9701 0.5058 0.2833 0.1967 0.1372 > 1:81000 secondary immunization M210048 3.4423 3.4091 3.126 2.7418 2.0721 1.193 0.5778 0.1252 > 1:243000 secondary immunization

[0057] 3. Cell fusion: two weeks after the last immunization, intraperitoneal injection of antigen was performed for booster immunization, and cell fusion was performed three days later. Mice were sacrificed by cutting their neck, soaked in 70% ethanol for 30 min for disinfection, and their abdominal cavity was cut open in the ultra-clean table. Spleen was removed, ground, and passed through 80 mesh screen to obtain splenocytes. SP2/0 myeloma cells were added, and cell fusion was carried out under action of PEG4000.

[0058] 4. Fusion screening: The fused cells were spread into a 96-well plate and cultured with HAT medium. After three days, medium was changed to HT medium. After 10 days, cell culture supernatant was taken for detection.

[0059] 5. Cloning and strain building: use the limited dilution method to clone the positive wells, 10 days later, the positive clones continue to be cloned by the limited dilution method, until the clones are all positive, positive cell lines can be established. Finally, 5 positive cell lines were obtained.

[0060] 6. Expanded culture: monoclonal cells of the established strain were expanded cultured and stored by freezing.

Preparation and Purification of Ascites

[0061] 1. Preparation of ascites: one week in advance, mice were intraperitoneally injected with mineral oil, and a certain number of cells were injected into mice., about 10 days later, ascites was collected and centrifuged at 4000 rpm to obtain supernatant as ascites of monoclonal antibody.

[0062] 2. Monoclonal antibody purification: ascites were centrifuged for 15 min (4000 rpm, room temperature), supernatant was taken, and saturated ammonium sulfate was slowly added drop by drop under stirring at 4° C. add to semi-saturation; stirring was continued for 30 min, centrifugation was performed for 30 min (13000 rpm, 4° C.), and supernatant was discarded; precipitate was dissolved in an appropriate amount of PBS(0.01 M, pH7.4), and slowly added with saturated ammonium sulfate drop by drop to 33% under stirring at 4° C.; continue stirring was continued for 30 min, centrifugation was performed for 30 min (13000 rpm, 4° C.), and supernatant was discarded. Precipitate was dissolved in an appropriate amount of PBS (0.01 M, pH 7.4), dialyzed at 4° C. overnight, antibody content was determined, and frozen at -20° C. for reserve. After ammonium sulfate precipitation, Protein G column was used for purification. New column was first passed with 5 mL ultrapure water, and then balanced with 5 mL 0.4 M PB buffer (pH 7.0) to purify the column; antibody was passed through the column with requirement of slow passing through the column in process, in order to better bind antibody protein on binding site; the column was subsequently equilibrated with 10 mL 0.4 M PB buffer (pH 7.0); the antibody at the binding site was eluted with 5 ml of 0.1 M glycine-hydrochloric acid buffer (pH 2.7) and glycine was neutralized by adding 1 M Tris-HCl (pH 8.0) to maintain a neutral pH suitable for antibody preservation.

Antibody Screening

[0063] 1. Titer detection Titer of purified antibody was detected by indirect ELISA method, and data were shown in Table 2:

TABLE-US-00002 Antibody number 100 1K 4K 16K 64K 256K 1024K Negative Titer FL484-1 2.926 2.909 2.866 2.823 2.760 2.552 2.232 0.169 > 1:1024k FL484-2 2.876 2.871 2.835 2.707 2.647 2.516 1.969 0.208 > 1:1024k FL484-3 2.847 2.833 2.797 2.739 2.659 2.453 1.938 0.140 > 1:1024k FL484-4 2.836 2.822 2.656 2.556 2.192 1.436 0.931 0.230 > 1:1024k FL484-5 2.882 2.803 2.789 2.778 2.718 2.220 1.951 0.237 > 1:1024k FL484-6 2.802 2.760 2.759 2.708 2.694 2.172 2.131 0.240 > 1:1024k FL484-7 2.960 2.936 2.936 2.927 2.881 2.699 2.462 0.240 > 1:1024k FL484-8 2.790 2.762 2.737 2.692 2.654 2.291 2.538 0.196 > 1:1024k FL484-9 2.484 2.460 2.458 2.439 2.438 2.362 2.176 0.171 > 1:1024k FL484-10 2.737 2.728 2.726 2.696 2.635 2.344 1.613 0.158 > 1:1024k FL484-11 2.544 2.509 2.503 2.484 2.460 2.292 1.835 0.052 > 1:1024k FL484-12 2.837 2.755 2.742 2.727 2.705 2.679 2.647 0.157 > 1:1024k FL484-13 2.660 2.526 2.548 2.390 2.236 2.180 1.718 0.155 > 1:1024k FL484-14 2.593 2.381 2.361 2.270 2.133 1.733 1.083 0.190 > 1:1024k FL484-15 2.730 2.546 2.511 2.444 2.250 1.943 1.469 0.187 > 1:1024k FL484-16 2.597 2.558 2.516 2.355 2.317 2.027 1.577 0.209 > 1:1024k FL484-17 2.763 2.745 2.532 2.529 2.234 1.693 1.087 0.186 > 1:1024k FL484-18 2.747 2.660 2.513 2.426 2.240 1.712 1.577 0.179 > 1:1024k FL484-19 2.782 2.740 2.648 2.620 2.528 2.401 2.232 0.164 > 1:1024k FL484-20 2.798 2.794 2.729 2.560 2.394 2.187 2.076 0.236 > 1:1024k FL484-21 2.571 2.478 2.431 2.348 2.288 2.184 2.001 0.180 > 1:1024k FL484-22 2.925 2.936 2.843 2.760 2.522 2.043 1.543 0.163 > 1:1024k FL484-23 2.655 2.455 2.251 2.212 2.193 1.921 1.286 0.232 > 1:1024k FL484-24 2.767 2.723 2.522 2.452 2.232 1.840 1.221 0.203 > 1:1024k FL484-25 2.421 2.412 2.306 2.328 2.115 1.764 1.411 0.234 > 1:1024k FL484-26 2.484 2.432 2.308 2.303 2.050 1.550 1.042 0.161 > 1:1024k FL484-27 2.469 2.451 2.287 2.289 2.120 1.682 1.167 0.197 > 1:1024k FL484-28 2.524 2.487 2.351 2.363 2.190 1.824 1.720 0.229 > 1:1024k FL484-29 2.591 2.480 2.274 1.825 1.137 1.189 0.969 0.215 > 1:1024k FL484-30 2.544 2.533 2.449 2.382 2.414 2.078 1.812 0.265 > 1:1024k FL484-31 2.645 2.570 2.484 2.359 2.355 2.105 1.936 0.172 > 1:1024k FL484-32 2.773 2.703 2.664 2.451 2.407 2.151 2.110 0.194 > 1:1024k FL484-33 2.469 2.385 2.219 2.108 1.940 1.427 1.863 0.221 > 1:1024k FL484-34 2.716 2.541 2.453 2.268 2.236 1.662 1.033 0.193 > 1:1024k FL484-35 2.492 2.480 2.456 2.363 2.216 2.133 1.851 0.190 > 1:1024k

[0064] 2. Subtype detection Mouse antibody subtype detection kit was used for subtype detection of antibodies, and results were shown in Table 3 and Table 4:

TABLE-US-00003 Antibody number IgA IgM IgG1 IgG2a IgG2b IgG3 κ λ FL484-0 1 0.185 0.234 1.76 0.189 0.15 0.149 1.355 0.145 FL484-02 0.161 0.209 1.903 0.168 0.195 0.134 1.477 0.127 FL484-03 0.189 0.200 1.85 0.218 0.137 0.129 1.371 0.129 FL484-04 0.161 0.223 1.949 0.148 0.135 0.129 1.413 0.124 FL484-05 0.183 0.192 1.901 0.146 0.126 0.117 1.372 0.146 FL484-06 0.181 0.227 2.12 0.166 0.129 0.134 1.537 0.134 FL484-07 0.152 0.176 1.959 0.165 0.116 0.103 1.386 0.124 FL484-08 0.229 0.201 2.000 0.177 0.105 0.121 1.397 0.124 FL484-09 0.179 0.195 1.953 0.161 0.137 0.102 1.341 0.133 FL484-10 0.244 0.244 2.002 0.167 0.096 0.123 1.451 0.137 FL484-11 0.197 0.271 2.001 0.177 0.112 0.125 1.387 0.157 FL484-12 0.262 0.271 2.024 0.185 0.110 0.154 1.489 0.158 FL484-13 0.073 0.058 1.555 0.057 0.058 0.054 1.328 0.075 FL484-14 0.059 0.054 1.816 0.053 0.052 0.050 1.375 0.063 FL484-15 0.07 0.051 1.831 0.054 0.053 0.047 1.312 0.052 FL484-16 0.091 0.055 1.639 0.055 0.053 0.050 1.312 0.056 FL484-17 0.065 0.058 1.742 0.055 0.050 0.050 1.346 0.061 FL484-18 0.079 0.058 1.726 0.055 0.053 0.049 1.311 0.057 FL484-19 0.077 0.061 1.867 0.054 0.045 0.043 1.358 0.052 FL484-20 0.087 0.059 1.784 0.053 0.047 0.045 1.310 0.050 FL484-21 0.080 0.057 1.946 0.056 0.051 0.048 1.411 0.052 FL484-22 0.077 0.059 1.954 0.054 0.048 0.047 1.322 0.058 FL484-23 0.083 0.056 1.661 0.054 0.052 0.051 1.381 0.053 FL484-24 0.08 0.056 1.875 0.058 0.049 0.051 1.337 0.056 FL484-25 0.106 0.075 1.741 0.070 0.063 0.057 1.390 0.061 FL484-26 0.08 0.064 1.597 0.058 0.055 0.052 1.338 0.064 FL484-27 0.092 0.076 1.744 0.063 0.056 0.049 1.398 0.060 FL484-28 0.176 0.125 2.134 0.091 0.067 0.074 1.125 0.095 FL484-29 0.138 0.079 2.056 0.061 0.150 0.062 1.065 0.066 FL484-30 0.223 0.206 1.580 0.183 0.177 0.195 1.084 0.163 FL484-31 0.183 0.135 1.643 0.182 0.183 0.207 0.985 0.184 FL484-32 0.135 0.155 0.077 0.088 1.631 0.107 1.08 0.109 FL484-33 0.001 0.163 1.642 0.183 0.162 0.221 1.000 0.104 FL484-34 0.228 0.153 1.628 0.201 0.176 0.186 0.982 0.185 FL484-35 0.201 0.171 1.650 0.174 0.165 0.166 0.801 0.191

TABLE-US-00004 Cell number Clone number Subtypes Light chain or heavy chain Ascites titer FL484-0 1 1G3-1G8-1H1 IgG1 K >1: 1024K FL484-02 1E6-2D1-1H9 IgG1 K >1: 1024K FL484-03 1H11-2E7-2D5 IgG1 K >1: 1024K FL484-04 2B3-3E2-2H9 IgG1 K >1: 1024K FL484-05 2B4-4C4-3B9 IgG1 K >1: 1024K FL484-06 2A6-4G8-4B2 IgG1 K >1: 1024K FL484-07 2F10-5F7-4D8 IgG1 K >1: 1024K FL484-08 3C3-7H9-6A2 IgG1 K >1: 1024K FL484-09 3E5-8B12-6F7 IgG1 K >1: 1024K FL484-10 4D2-9B3-7D5 IgG1 K >1: 1024K FL484-11 7F8-18D9-15C4 IgG1 K >1: 1024K FL484-12 8A1-19G5-15A8 IgG1 K >1: 1024K FL484-13 8F9-21D4-17D3 IgG1 K >1: 1024K FL484-14 10E2-23A7-18E4 IgG1 K >1: 1024K FL484-15 7B4-17D1-14B5 IgG1 K >1: 1024K FL484-16 10C7-24F8-19H2 IgG1 K >1: 1024K FL484-17 10B11-25B8-19C7 IgG1 K >1: 1024K FL484-18 5H6-13D 10-10C8 IgG1 K >1: 1024K FL484-19 4D8-10E2-8G1 IgG1 K >1: 1024K FL484-20 4E9-10G7-8H8 IgG1 K >1: 1024K FL484-21 4A10-11A3-9A2 IgG1 K >1: 1024K FL484-22 5G3-12D9-9H8 IgG1 K >1: 1024K FL484-23 5D5-13H3-10G6 IgG1 K >1: 1024K FL484-24 5H7-14G3-11C1 IgG1 K >1: 1024K FL484-25 6D2-15B2-12G2 IgG1 K >1: 1024K FL484-26 7G3-16H9-13B7 IgG1 K >1: 1024K FL484-27 3F2-6F7-5G2 IgG1 K >1: 1024K FL484-28 7F6-18E1-14H8 IgG1 K >1: 1024K FL484-29 8D8-20B8-16E7 IgG1 K >1: 1024K FL484-30 9A7-21E11-17H7 IgG1 K >1: 1024K FL484-31 10D4-24E1-18D10 IgG1 K >1: 1024K FL484-32 4H4-9E10-7E8 IgG2b K >1: 1024K FL484-33 5E12-14H8-11E8 IgG1 K >1: 1024K FL484-34 6H7-16G1-13C3 IgG1 K >1: 1024K FL484-35 6C7-15F8-12F10 IgG1 K >1: 1024K

[0065] 3. Antibody pairing The obtained antibody was screened by gold labeled method of double antibody sandwich, and the antibody pairs which could be paired were screened out.

[0066] Among them, FL484-03 and FL484-10 had the best pairing effect, so this pair of antibodies was selected as antibody for preparing subsequent colloidal gold rapid test strip, and this pair of antibodies was deposited.

[0067] 4. Strip specificity detection Cross reaction of TMV, PVY, TSWV, ChiVMV and other common tobacco viruses was detected, and results showed that there was no cross reaction between the antibodies and other plant viruses. The result was shown in FIG. 2, from left to right, there were TMV, PVY, TSWV, ChiVMV, TZSV positive leaf samples determined by RT-PCR.

[0068] Experimental conclusion: The test strip provided by the invention has specificity for TZSV, and no specific reaction to other viruses like TMV, PVY, TSWV and ChiVMV

Example 3. TZSV Hand-Held Colloidal Gold Rapid Test Strip Production

[0069] TZSV hand-held colloidal gold rapid test strip provided in this example (TZSV virus immunoassay test card) consists of a sample pad, gold labeled pad, nitrocellulose membrane, absorbent pad (absorption pad) and a backplane; sample pad, gold labeled pad, nitrocellulose membrane and absorbent pad are successively superimposed and pasted on the backplane, and each part is superimposed between each other by 2.5 mm; the gold labeled pad was coated with colloidal gold labeled anti-TZSV monoclonal antibody; nitrocellulosic membrane is provided with a test line and a quality control line (T line and C line), the test line is coated with anti-TZSV monoclonal antibody, the quality control line is coated with anti-mouse IgG secondary antibody.

[0070] Wherein, the anti-TZSV monoclonal antibody was secreted and produced by hybridoma cell lines with depository numbers of CCTCC No. C202160 and CCTCC No. C202196.

[0071] Concentration of anti-mouse IgG secondary antibody coated on the quality control line was 1 mg/ml. Size of the sample pad is 3 mm × 15 mm, size of the gold labeled pad is 3 mm×3 mm, size of the nitrocellulose membrane is 3 mm×28 mm, and size of the absorption pad is 3 mm×19 mm.

[0072] Space between the test line and the quality control line is 6-6.5 mm.

[0073] The backplane (bottom plate) is a PVC board.

[0074] Production method of the test card is as follows: [0075] 1. Preparation of nitrocellulose membrane containing test line T and quality control line C [0076] 1) Preparation of coated murine monoclonal antibody [0077] TZSV murine monoclonal antibody was diluted to 1 mg/mL with PBS buffer solution of 10 mM and pH 7.4 to obtain TZSV murine monoclonal antibody solution, which was used as coated murine monoclonal antibody for test line T. [0078] Sheep anti-mouse IgG secondary antibody solution was diluted to 1 mg/ mL in PBS buffer solution with concentration of 10 mM and pH of 7.4, which was used as coated mouse monoclonal antibody for quality control line C. [0079] 2) Coat [0080] Nitrate cellulose membrane (NC film) of PALL170 was selected, and TZSV murine monoclonal antibody solution with a concentration of 1.0 mg/mL was drawn T line at 1.0 .Math.L/cm with Dispenser and Sprayer, which was used as the test line; sheep anti-mouse IgG secondary antibody solution with a concentration of 1 mg/mL was drawn C line with 1.0 .Math.L/cm as the quality control line; they were dried at 37° C. for 24 hours and stand-by; the nitrocellulose membrane coated with murine monoclonal antibody was obtained. [0081] 2. Preparation of gold labeled pad [0082] 1) Colloidal gold preparation [0083] a) Preparation: 500 mL beaker, 20 mL small beaker, rotor, brown bottle, glass rod, etc. were washed out, put into acid cylinder (potassium bichromate: concentrated sulfuric acid: ultra-pure water = 120 g:200 ml: 1000 ml) and soaked for 24 hours. They were taken out, rinsed 3-4 times with tap water, then rinsed 3-4 times with ultrapure water, and put in oven to dry at 37° C. for reserve. [0084] b) preparation of gold burning solution A: 1 g chloroauric acid powder (purchased from Sigma) was weighed with a plastic weighing spoon in a brown bottle, fully dissolved by adding 99 mL ultra-pure water, and stored at 4° C. with avoiding light. [0085] c) preparation of gold burning solution B: 1 g trisodium citrate (purchased from Sigma) was weighed, dissolved in 99 mL ultra-pure water and mixed well. [0086] d) Preparation of colloidal gold: 99 ml ultrapure water was measured out in beaker, 1 ml gold burning solution A was added; mixture were stirred and mixed well on constant temperature magnetic stirrer; mixture was heated to boiling, 2 ml newly prepared burning gold solution B was added quickly, stirred and heated subsequently; solution gradually became a blue-black, then purple black; when reheating solution appeared red, and became transparent orange red by continuously boiling; solution was continuously boiled for 10 min, cooled naturally to room temperature, and added ultrapure water to 100 ml. Solution was poured into a brown bottle and stored at 4° C. with avoiding light; the colloidal gold solution was obtained (particle size of colloidal gold was 40 nm, and concentration is one part in ten thousand). [0087] 2) Murine monoclonal antibody labeling [0088] e) Labeling of murine monoclonal antibody: 1.5 ml of colloidal gold solution prepared by above step 1) was taken, adjusted pH value with 0.1 M K.sub.2CO.sub.3, added 20 .Math.g TZSV monoclonal murine monoclonal antibody, mixed well, and reacted at room temperature for 40 min. Reaction was terminated by adding 10% BSA and placed for 30 min. [0089] f) Purification of labeled murine monoclonal antibody: products obtained by above step e) was centrifuged at low speed (1500 r/min), precipitation formed by condensed gold colloides was discarded, and supernatant was collected; such supernatant was centrifuged at high speed (8500 r/min) for 30 min, with supernatant carefully removed, and precipitate was collected. Precipitate was redissolved in 0.1 M PBS (pH 7.4) containing 1% (mass percentage) BSA and stored at 4° C. The labeled colloidal gold TZSV murine monoclonal antibody solution was obtained with concentration of 0.4 mg/ml. [0090] 3) Spray gold [0091] The labeled colloidal gold TZSV mouse monoclonal antibody solution with concentration of 0.4 mg/ mL prepared by above step 2) was sprayed on the pretreated gold labeled pad with 1.0 .Math.L/cm, dried and ready for use, and the gold label pad fixed with colloidal gold labeled specific monoclonal mouse monoclonal antibody was obtained. [0092] 3. Assembly and cutting [0093] The sample pad, gold labeled pad fixed with colloidal gold labeled anti-TZSV monoclonal antibody, nitrocellulose membrane and absorbent pad were pasted onto the backplane in turn, and cut into 3 mm wide with a strip cutter to obtain the TZSV colloidal gold rapid test strip.

Example 4. Evaluation on Effect of TZSV Virus Immunoassay Test Card in Detecting Virions

[0094] 1. 200 .Math.l blank sample solution (pH 7.4, 0.2 M/L PBS solution) was added into the sample cup, and the preparation method was as follows: 8 g sodium chloride, 3.35 g disodium hydrogen phosphate dodecahydrate, 0.2 g potassium dihydrogen phosphate and 0.2 g potassium chloride was dissolved by double steamed water to a constant volume of 1 L. The test strip was inserted into the sample cup rapidly, and the color development results were observed in the result observation area after 8 minutes of reaction at room temperature. The results show that T line did not produce color in the observation area, while C line did.

[0095] 2. 100 .Math.l of 0.1 .Math.g/ml TZSV virus standard (prepared with above PBS solution) was added into the sample cup, and the same procedure as the blank sample was performed.

[0096] The results show that C line and T line produce color simultaneously in the observation area. Experimental conclusion: The TZSV virus detection reagent of the invention can quickly detect TZSV virus, and has high sensitivity and convenient operation.

Example 5. Evaluation on Effect of TZSV Virus Immunoassay Card on Real Leaf Samples

[0097] 1. 200 .Math.l of negative leaf sample extract was added into the sample cup and performed according to the same procedure as the standard (same as step 1 of example 4). The results show that only the control line C produced color in the observation area, while the test line T did not.

[0098] 2. 200 .Math.l positive leaf sample extract was added into the sample cup, and performed according to the same procedure as negative sample.

[0099] The results show that both the control line C and the test line T produce color in the observation area. Experimental conclusion: The TZSV virus hand-held colloidal gold speed test strip of the invention has good anti-interference effect on leaf and other samples, and can be widely used in rapid detection of TZSV, with high sensitivity and convenient operation.

Example 6. Preparation and Performance Verification of TZSV Test Strip

6.1 Prokaryotic Expression of N Protein in Yunnan Province TZSV Lines

[0100] This example performed theoretical evaluation on hydrophilicity or hydrophobicity, signal peptide, transmembrane domain, basic structure of N protein in TZSV Yunnan strain, plasmid construction program was designed according to results of the evaluation with method of full gene synthesis to construct plasmid, clone into expression vector, further transform into a competent escherichia coli cells, culture, induced express, collect bacteria, purify protein. Finally, 5 mg recombinant TZSV-N protein with purity >90% was obtained and verified by SDS-PAGE.

[0101] Gene sequence with optimized codon was shown in SEQ ID NO.2, with 6 bases at 5 ‘end and 6 bases at 3’ end as restriction sites.

[0102] Amino acid sequence of prokaryotic expressed TZSV-N Protein was shown in SEQ ID NO.1. Protein Length=282 AA, MW= 31 KDa (34 KDa with label), Predicted pI= 8.6.

[0103] Protein expression and verification

[0104] After purification, fusion protein can be expressed in a large amount in supernatant, and it has been proved that the maximum amount of the fusion protein can be purified by elution of imidazole at a concentration of 200-500 mM. It’s preliminarily to determine that the fusion protein was purified successfully when results of SDS-PAGE showed that there were obvious bands in the corresponding position of theoretical molecular weight ±5 kDa. Electrophoresis results of pET28a-TZSV-N protein purification are shown in FIG. 3.

[0105] TZSV N protein was successfully expressed and purified by pET28a vector. After purification, 10 ml of target protein was obtained at a concentration of 0.5 mg/ml, whose total weight was 5 mg, and was packed according to 1 ml/tube.

[0106] Protein storage buffer: 20 mM Tris-Cl, 50 mM NaCl, 1 mM EDTA, pH=8.0.

6.2 Preparation of TZSV Mab

[0107] Four 6-week-old female BALB/ C mice were immunized for three times by subcutaneous multipoint injection. Antigen dosage of each mouse was 25 .Math.g, the first immunization was emulsified with same volume of Freund’s complete adjuvant, the second immunization was emulsified with same volume of Freund’s incomplete adjuvant, and the third immunization was mixed with same volume of normal saline and injected intraperitoneally. Specific immunization procedures are shown in Table 5.

TABLE-US-00005 preparation of immunization protocol of monoclonal antibodies preparation Number of immune Date of immune Interval Adjuvant type Site and method of immunity First time 2020/4/25 0 Freund’s complete adjuvant Subcutaneous multipoint injection Second time 2021/5/8 13 Freund’s incomplete adjuvant Subcutaneous multipoint injection Third time 2021/5/28 20 Physiological saline Intraperitoneal injection

[0108] Twenty days after the second immunization, blood was collected from tail vein and antibody titers were measured by an indirect method to determine whether antibodies against antigen had been generated. Titers of four mice were compared, and the mouse with higher antibody titer was finally selected for cell fusion (mouse number: M210045). Three days before fusion, booster immunization was performed directly with antigen and with same dose as before.

[0109] A total of 37 positive monoclonal hybridoma cell lines were screened and established. The hybridoma cells were collected, and mouse ascites were prepared and collected, the 1000-fold dilution of TZSV positive samples collected in field was used as sample to be tested, and antibody titer was determined by indirect ELISA method. The titer can be as high as 1:1024000. Results of monoclonal antibody titer detection are shown in Table 6.

TABLE-US-00006 TZSV N protein mouse monoclonal antibody assay (partial) Cell number Detection original Coated concentration 100 16K 64K 256K 1024K Titer Negative samples FL484-9 Positive tobacco 0.74 1.82 1.24 1.15 0.98 0.62 1024K 0.39 FL484-11 Positive tobacco 0.74 1.18 0.79 0.64 0.36 0.25 64K 0.29 FL484-19 Positive tobacco 0.74 1.32 0.76 0.56 0.37 0.26 64K 0.29 FL484-21 Positive tobacco 0.74 1.20 0.78 0.58 0.36 0.26 64K 0.20 FL484-34 Positive tobacco 0.74 1.80 0.78 0.53 0.30 0.23 64K 0.37 FL484-35 Positive tobacco 0.74 1.34 0.96 0.75 0.48 64K 0.24

6.3 TZSV ELISA Kit Development

[0110] Antibody with good performance in preliminary experiment was selected to be paired with polyclonal antibody, the results in Table 7 showed that the monoclonal antibody with No. 3#, 9#, 10, 21, 37 could detect recombinant protein with a sensitivity of more than 10 PPB when they were paired with polyclonal antibody, and all of them could detect TZSV tobacco leaf samples that were pathogenetic in field; 9# monoclonal antibody was selected for subsequent enzyme-labeled product optimization.

TABLE-US-00007 Detection on effect of TZSV monoclonal antibody Mab number Recombinant protein Positive tobacco leaf sample 1 Positive tobacco leaf sample 2 1 ppm 100 ppb 10 ppb 0 10x 100x 10x 100x 3# 3.7328 1.385 0.1943 0.0741 3.5855 3.4265 1.4824 1.3598 9# 3.7364 1.5564 0.3963 0.2371 3.5519 3.6975 3.4816 3.5113 10# 3.7521 2.9797 0.66 0.059 2.7301 2.4701 1.8265 1.483 21# 3.8608 2.3165 0.3963 0.1149 3.5117 3.5395 2.6189 2.4474 37# 3.9104 2.6782 0.5833 0.1469 3.4838 3.4129 2.802 2.5955

9# monoclonal antibody was selected as the coated antibody, and standard product with gradient concentration was prepared through condition optimization. Linear range of 10-160 ppb was selected as detection range (Table 8), and standard curve was obtained through linear regression (FIG. 4).

TABLE-US-00008 Optimization conditions of 9# monoclonal antibody ODI OD2 Average OD Recombinant protein ppb 320 2.8612 2.8861 2.8737 160 2.0368 1.8921 1.9645 80 12554 1.2249 1.2402 40 0.8287 0.7174 0.7731 20 0.5353 0.4904 0.5129 10 345 0.3174 0.3312 5 0.2531 0.2454 0.2493 0 0.1956 0.1678 0.1817 Sample100 x 3.5307 34329 3.4818 Sample IK x 0.98 0.9962 0.9881 Sample10K x 0.253 0.2478 0.2504 Negative samples 0.1448 0.1467 0.1458

6.4 Preparation of TZSV Test Strip

[0111] Firstly, sensitivity of test strip was tested. As shown in FIG. 5, from left to right, the three groups are No. 9 monoclonal antibody labeled gold/No. 55 monoclonal antibody spray film, No. 10 monoclonal antibody labeled gold/No. 55 monoclonal antibody spray film, and No. 45 monoclonal antibody labeled gold/No. 55 monoclonal antibody spray film. From left to right in each group there were 0, 10 ppm, 1 ppm, 500 ppb, and 100 ppb of recombinant proteins as antigens. The test strip of monoclonal antibody No. 10 standard gold/monoclonal antibody No. 55 spray film can reach result that line appears indistinctly at 500 ppb (FIG. 5A). TZSV positive tobacco leaf samples pathogenetic in field were used for sensitivity detection. Supernatant after grinding 0.1 g fresh pathogenetic leaves and adding 1 mL PBS to mix and centrifuge was used as 10.sup.-1 times dilution of virus diluent, and 10.sup.-2, 10.sup.-3, 10.sup.-4, and 10.sup.-5 times dilution of virus diluent were prepared successively. 150 .Math.L dilution of each was used to test sensitivity of the test strip. Results showed that the test strip of No. 10 mab standard gold/No. 55 mab spray film had the best sensitivity, and the T-line was still clearly visible when virus diluent was diluted 10.sup.-4 times, while line appears indistinctly when virus diluent was diluted 10.sup.-5 times (FIG. 5B).

[0112] TMV, PVY, CMV, TVBMV, ChiVMV, TSWV and TZSV infected leaves which were identified as positive by RT-PCR were used as test samples to detect specificity of TZSV test strip. As shown in FIG. 6, only TZSV samples showed positive reaction, while other virus-positive samples showed negative results, indicating that TZSV test strip had good specificity.

[0113] Evaluation on stability of TZSV strip: Test strip was placed in an environment of 4° C., room temperature and 37° C. for 6 months, during this period, test strip was taken out to test 100-fold dilution of negative control and TZSV positive sample every other month, and results are shown in Table 9, during the stability evaluation period of 6 months, the test strip maintained good stability at three temperatures, and no false positives or false negatives occurred.

TABLE-US-00009 TZSV test strip stability test treatment Time/Month 0 1 2 3 4 5 6 Positive 4 ° + + + + + + + Room temperature + + + + + + + 37 ° + + + + + + + Negative 4 ° — — — — — — — Room temperature — — — — — — — 37 ° — — — — — — —